CDK8 as a therapeutic target for overall survival prediction in cervical squamous cell carcinoma (CESC).

IF 2.3 4区医学 Q3 ONCOLOGY Current cancer drug targets Pub Date : 2025-01-24 DOI:10.2174/0115680096332050241022102545

Feiting Xie, Qiugang Zhu, Shizhou Yang, Xiaofen Jin, Danqi Ruan, Lingfang Wang, Yang Li, Fang Ren, Xiaojing Chen

{"title":"CDK8 as a therapeutic target for overall survival prediction in cervical squamous cell carcinoma (CESC).","authors":"Feiting Xie, Qiugang Zhu, Shizhou Yang, Xiaofen Jin, Danqi Ruan, Lingfang Wang, Yang Li, Fang Ren, Xiaojing Chen","doi":"10.2174/0115680096332050241022102545","DOIUrl":null,"url":null,"abstract":"<p><p>Cyclin-dependent kinase 8 (CDK8) is a paracrine transcriptional regulator involved in regulating cellular stress response, growth, and neurological functions, in conjunction with mediator complex subunits 12 (MED12), MED13, and cyclin C.Cyclin-dependent kinase 8 (CDK8) is a paracrine transcriptional regulator involved in regulating cellular stress response, growth and neurological functions，in conjunction with mediator complex subunit 12 (MED12), MED13 and cyclin C. Studying the relationship between CDK8 and cervical squamous cell carcinoma (CESC) has significant clinical implications in diagnosis, treatment, and prognosis. We analyzed the relationship between CDK8 and poor prognosis of CESC. The results indicated that CDK8 was overexpressed in CESC, and the survival rate of patients in the CDK8 hypermethylation group was higher than that in the CDK8 hypomethylation group. In addition, CDK8 was associated with immune cell infiltration in tumor tissues. Overall, these findings provide more evidences for the relationship between CDK8 and patient's overall survival, which could provide insights into clinical diagnosis and prognosis prediction for CESC.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096332050241022102545","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cyclin-dependent kinase 8 (CDK8) is a paracrine transcriptional regulator involved in regulating cellular stress response, growth, and neurological functions, in conjunction with mediator complex subunits 12 (MED12), MED13, and cyclin C.Cyclin-dependent kinase 8 (CDK8) is a paracrine transcriptional regulator involved in regulating cellular stress response, growth and neurological functions，in conjunction with mediator complex subunit 12 (MED12), MED13 and cyclin C. Studying the relationship between CDK8 and cervical squamous cell carcinoma (CESC) has significant clinical implications in diagnosis, treatment, and prognosis. We analyzed the relationship between CDK8 and poor prognosis of CESC. The results indicated that CDK8 was overexpressed in CESC, and the survival rate of patients in the CDK8 hypermethylation group was higher than that in the CDK8 hypomethylation group. In addition, CDK8 was associated with immune cell infiltration in tumor tissues. Overall, these findings provide more evidences for the relationship between CDK8 and patient's overall survival, which could provide insights into clinical diagnosis and prognosis prediction for CESC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.